“…Most of the studies that carried out trials of the application of EMF in the management of any pathology were developed in accordance with Declaration of Helsinki (Casalechi et al, 2020;Elshiwi et al, 2019;Mohajerani et al, 2019;Multanen et al, 2018) or endorsed by institution's ethics committee. Some studies used measurement scales to know the level of improvement in both pain, inflammation or disability of patients, such as visual analog scale (VAS) (Hattapoğlu et al, 2019;Kopacz et al, 2020), Western Ontario and McMaster Universities Osteoarthritis Index ( WOMAC) (Bagnato et al, 2016;Chen et al, 2019), Fibromyalgia Impact Questionnaire (FIQR) (Paolucci et al, 2016), Generalized Pain Index (WPI) (El Zohiery et al, 2021), Numerical Pain Rating Scale (NRS) (Abdulla et al, 2019;El Zohiery et al, 2021), Health Assessment Questionnaire (HAQ) (Paolucci et al, 2016) and American Spinal Injury Association (ASIA, Tarlov Scale (Ross et al, 2017). It is important to highlight that there were several modalities of EMF therapy approved by the Food and Drug Administration, where one of them was the PEMF, which is one of the most used therapies in the studies analyzed (Hu et al, 2020;Iwasa & Reddi 2018;Pesqueira et al, 2018;Ross et al, 2017;Vicenti et al, 2018).…”